Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06344819 · ClinicalTrials.gov registry record · Phase 2

An Acupuncture Study for People At High Risk for Sepsis

A Phase 2 study of Sepsis, sponsored by Memorial Sloan Kettering Cancer Center.

Recruiting
Registry status
Phase 2
Development phase
78
Enrollment target
1
Study location

NCT06344819 is a Phase 2 study of Sepsis that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 78 participants, below the 6,564-participant average among 90 other Sepsis trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06344819, a Phase 2 study of Sepsis, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.

RECRUITING
Registry status
Phase 2
Development phase
78 participants
Enrollment target
1
Study location

Study Summary

Researchers think acupuncture may improve outcomes for participants with sepsis, based on laboratory studies and previous studies in people with sepsis. The purpose of this study to see whether real acupuncture can improve outcomes for participants with sepsis when compared to sham acupuncture. Sham acupuncture is performed the same way as real acupuncture but will use different needles and target different sites or places on the body than real acupuncture.

Conditions Studied

Interventions

  • PROCEDURE Acupuncture
  • OTHER Sham Acupuncture

Study Locations (1)

New York

  • Memorial Sloan Kettering Cancer Center - New York

Trial Details

FieldValue
Enrollment Target 78 participants
Start Date 2024-03-20
Est. Completion 2028-03-20
Phase Phase 2

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

What the Registry Record Tells You About NCT06344819

The ClinicalTrials.gov registry entry for NCT06344819 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 6,564-participant average among 90 other Sepsis trials with a reported enrollment target (99% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Sepsis appearing as the primary indexed condition, and to 2 interventions - of which Acupuncture is the first listed.

NCT06344819 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT06344819 about?

NCT06344819 is a clinical study titled "An Acupuncture Study for People At High Risk for Sepsis". Researchers think acupuncture may improve outcomes for participants with sepsis, based on laboratory studies and previous studies in people with sepsis. The purpose of this study to see whether real acupuncture can improve outcomes for participants with sepsis when compared to sham acupuncture. Sham...

What is the current status of trial NCT06344819?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2024-03-20. Estimated completion is 2028-03-20.

What conditions does trial NCT06344819 study?

This clinical trial studies the following conditions: Sepsis.

What interventions are being tested in trial NCT06344819?

The interventions under investigation include: Acupuncture (PROCEDURE), Sham Acupuncture (OTHER).

Who is sponsoring clinical trial NCT06344819?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06344819 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sepsis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.